GET DAILY SIGNALSBeyond Air (XAIR) Shares Dip After Record Quarter: Watching the -8% Pullback
Key Takeaways
- Beyond Air (XAIR) is a commercial-stage medical device company focused on cylinder-free inhaled nitric oxide (NO) therapy; its LungFit PH system holds FDA approval and a CE Mark for neonatal hypoxic respiratory failure.
- Over the past 30 days, shares have declined roughly 8%, moving from about $2.19 to near $2.01 amid a sharp post-earnings reversal.
- The company posted record quarterly revenue of $2.3 million for the quarter ended September 30, 2026, up approximately 28% year over year, while reporting a net loss of $7.8 million.
- Management reaffirmed calendar 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, with the latter tied in part to anticipated second-generation LungFit PH sales.
- Cash, restricted cash, and marketable securities totaled $18.5 million at quarter-end, keeping liquidity and financing considerations central to the investment case.
Current Trading Picture
Beyond Air shares have been trading in a volatile range as investors weigh improving commercial momentum against a still-unprofitable operating profile. After climbing on the back of record quarterly results, the stock pulled back sharply, leaving it roughly 8% lower over the trailing 30 days, from about $2.19 to near $2.01. The reversal highlights how quickly sentiment can shift in a thinly traded, pre-profitability healthcare name where near-term catalysts, particularly regulatory decisions, dominate price action.
Beyond Air (XAIR) Business Overview and Competitive Position
Beyond Air is a commercial-stage medical device and biopharmaceutical company built around the therapeutic use of nitric oxide. Its flagship product, LungFit PH, is a cylinder-free, phasic-flow generator that produces inhaled NO on demand from ambient air, eliminating the need for large, high-pressure NO cylinders in hospital settings. The system is FDA-approved and CE-marked for the treatment of hypoxic respiratory failure in term and near-term neonates, a condition also known as persistent pulmonary hypertension of the newborn.
The company is advancing a second-generation LungFit PH system that is smaller, lighter, and simpler to operate, and that would add patient-transport capability, potentially positioning Beyond Air as a single-source NO provider across routine care and transport. Its pipeline also includes LungFit GO, which received FDA breakthrough device designation for nontuberculous mycobacterial pulmonary disease. Investors follow XAIR closely because its growth story depends on hospital adoption, recurring revenue expansion, and a pending FDA decision on the next-generation platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Developments Driving XAIR
The most significant recent event was the November 11 earnings release for the quarter ended September 30, 2026. Beyond Air reported record revenue of $2.3 million, up about 28% year over year and 31% sequentially, while gross margin improved to approximately 8% from negative 16% a year earlier. The net loss attributable to common stockholders narrowed to $7.8 million, or $3.76 per share. Management also reaffirmed full-year revenue guidance, including $8 million for calendar 2026 and $16 million to $18 million for 2027.
Despite the revenue beat, shares reversed sharply in the following session, reflecting concern over the wider-than-expected loss, a thin cash position of $18.5 million, and ongoing uncertainty around FDA clearance. The second-generation LungFit PH PMA supplement remains under FDA review, with the company targeting audit readiness in mid-December before any inspection and final decision. Earlier in the period, Beyond Air also agreed to sell its controlling interest in its NeuroNOS subsidiary to UNIVO Pharmaceutical Industries and indicated it is evaluating strategic options for its Beyond Cancer program, moves aimed at sharpening focus on the core LungFit franchise.
2026 Outlook and What Investors Should Watch
The clearest catalyst ahead is the FDA's decision on the second-generation LungFit PH system. Approval, including the requested transport labeling, could materially broaden the company's addressable market and support the higher 2027 revenue outlook. Investors should monitor the audit-readiness timeline, any subsequent FDA inspections, and the timing of a final ruling. Beyond regulation, key factors include the pace of hospital account wins and renewals, gross margin progression, and whether the company can fund operations without substantial dilution given its $18.5 million cash balance. The transition of the fiscal year-end to December 31 and the planned nine-month transition report on Form 10-K/T are also worth tracking, as they may shape how results are reported and compared going forward. From what I see, the cash runway remains a key variable here.
How I Incorporate Tickeron AI Tools
In my own research on names like XAIR, I often turn to Tickeron’s AI Trading Bots to test different automated strategies and see how they have historically handled similar small-cap healthcare situations. It helps me cross-check my manual analysis without replacing it. The platform’s range of bots, from short-term signals to longer trend models, gives a useful additional perspective on volatility and potential entry points.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XAIR's RSI Indicator recovers from oversold territory
The RSI Oscillator for XAIR moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 35 of the 42 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on XAIR as a result. In 81 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +13.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where XAIR advanced for three days, in 174 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 44 cases where XAIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XAIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
XAIR broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XAIR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.084) is normal, around the industry mean (4.142). P/E Ratio (-0.036) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.213) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. XAIR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XAIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in the development of nitric oxide (NO) generator and delivery system.
Industry MedicalNursingServices
Advertisement